Changes

Jump to: navigation, search

Traumatic Brain Injury

909 bytes added, 10:02, 22 December 2022
State of the Art
|https://www.avivasysbio.com/gfap-elisa-kit-bovine-okcd02567.html https://www.avivasysbio.com/pub/media/pdf/products/OKCD02567.pdf
|-
|}<div style="margin-bottom:1em"><sub>''Table 1: Commercially available GFAP well-plate ELISA test assays.</sub><br/> As is clear from the above table, the classic ELISA technique is widely available as commercial kits, which makes it a convenient method for biomarker detection in patient samples. Nevertheless, a relatively long detection time (of at least a few hours) and the requirement of a laboratory environment precludes its use in GP surgeries or patients’ homes (Xu et al., 2021b). Classic ELISAs are laboratory-based assay, which are not suited for rapid testing as targeted in the SensUs competition.The same applies to more advanced laboratory assays, such as mass spectrometry and single molecular array (Simoa) technology.Recently a commercial GFAP test has been developed by Abbott on its i-STAT Alinity biosensor platform. The specifications are listed in the Table below. The i-STAT platform is used in hospitals. However, the i-STAT TBI Plasma test is not intended to be used in point-of-care settings.
== Lab protocols ==

Navigation menu